Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: jnj-26483327, tolimidone, dasatinib anhydrous +6 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 12 Parkinson's papers of 2,998 | 0.66 |
| pathways Reactome | 37 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 7103
Sealed predictions
- LYN in dopamine neurons, braak-0.29 (p 0.449) → -0.48 (p 0.186)receipt 7111
Swarm cases
receipt 7111: LYN in dopamine neurons, braak
- power
- full sample -0.42 (p 0.084, n 18), 95% CI -0.74 to +0.06. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.36 (p 0.145, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.35 (p 0.150, n 18). could be the mix.
- skeptic
- leave-one-out range -0.60 to -0.35, sign flips 0; without severely affected donors -0.42 (p 0.084, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LYN in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts